Skip to main content

Table 2 Responses to nivolumab treatment

From: CA19-9 in combination with P-CRP as a predictive marker of immune-related adverse events in patients with recurrent or unresectable advanced gastric cancer treated with nivolumab

  

irAE ( +) (n = 15)

irAE ( −) (n = 63)

CR

2 (2.6)

1 (6.7)

1 (1.6)

PR

8 (10.2)

3 (20.0)

5 (7.9)

SD

29 (37.2)

9 (60.0)

21 (33.3)

PD

39 (50.0)

2 (13.3)

36 (57.2)

ORR

10 (12.8)

4 (26.7)

6 (9.5)

DCR

39 (50.0)

13 (86.7)

27 (42.8)

  1. CR Complete response, PR Partial response, SD Stable disease, PD Progressive disease, ORR Objective response rate, (CR + PR) * 100 / total cases DCR, Disease control rate, (CR + PR + SD) * 100 / total cases
Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us